Announcement on the employment of the company's 2021 audit institution.
Release time:
2021-05-20
证券代码:600668 证券简称:尖峰集团 公告编号:2021-008
浙江尖峰集团股份有限公司
关于聘请公司2021年度审计机构的公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要内容提示
● 拟聘任的会计师事务所名称:天健会计师事务所(特殊普通合伙)
一、拟续聘会计师事务所的基本情况
(一)机构信息
1、基本信息
|
事务所名称 |
天健会计师事务所(特殊普通合伙) |
||||||
|
成立日期 |
2011年7月18日 |
组织形式 |
特殊普通合伙 |
||||
|
注册地址 |
浙江省杭州市西湖区西溪路128号6楼 |
||||||
|
首席合伙人 |
胡少先 |
上年末合伙人数量 |
203人 |
||||
|
上年末执业人员数量 |
注册会计师 |
1,859人 |
|||||
|
签署过证券服务业务审计报告的注册会计师 |
737人 |
||||||
|
2020年业务收入 |
业务收入总额 |
30.6亿元 |
|||||
|
审计业务收入 |
27.2亿元 |
||||||
|
证券业务收入 |
18.8亿元 |
||||||
|
2020年上市公司(含A、B股)审计情况 |
客户家数 |
511家 |
|||||
|
审计收费总额 |
5.8亿元 |
||||||
|
涉及主要行业 |
制造业,信息传输、软件和信息技术服务业,批发和零售业,房地产业,建筑业,电力、热力、燃气及水生产和供应业,金融业,交通运输、仓储和邮政业,文化、体育和娱乐业,租赁和商务服务业,水利、环境和公共设施管理业,科学研究和技术服务业,农、林、牧、渔业,采矿业,住宿和餐饮业,教育,综合等 |
||||||
|
本公司同行业上市公司审计客户家数 |
382 |
||||||
2、投资者保护能力
上年末,天健会计师事务所(特殊普通合伙)累计已计提职业风险基金1亿元以上,购买的职业保险累计赔偿限额超过1亿元,职业风险基金计提及职业保险购买符合财政部关于《会计师事务所职业风险基金管理办法》等文件的相关规定。
近三年天健会计师事务所(特殊普通合伙)已审结的与执业行为相关的民事诉讼中均无需承担民事责任。
3、诚信记录
天健会计师事务所(特殊普通合伙)近三年因执业行为受到监督管理措施12次,未受到刑事处罚、行政处罚、自律监管措施和纪律处分。32名从业人员近三年因执业行为受到监督管理措施18次,未受到刑事处罚、行政处罚和自律监管措施。
(二)项目信息
1、基本信息
|
项目组成员 |
姓名 |
何时成为注册会计师 |
何时开始从事上市公司审计 |
何时开始在本所执业 |
何时开始为本公司提供审计服务 |
近三年签署或复核上市公司审计报告情况 |
|
项目合伙人/签字注册会计师 |
毛晓东 |
1998年 |
1996年 |
1998年 |
1997年 |
2020年,签署九洲药业、尖峰集团等2019年度审计报告; 2019年,签署浙大网新、祥和实业等2018年度审计报告; 2018年,签署了祥和实业2017年度审计报告。 |
|
签字注册会计师 |
吴学友 |
2010年 |
2008年 |
2010年 |
2008年 |
2020年签署尖峰集团、甬金股份等2019年度审计报告; 2019年签署尖峰集团、长城科技等2018年度审计报告; 2018年签署尖峰集团等2017年度审计报告。 |
|
质量控制复核人 |
毛育晖 |
1997年 |
1997年 |
1997年 |
2021年 |
2020年复核了大参林、益丰药房、兴图新科等上市公司年度审计报告; 2019年复核了大参林、宇环数控、隆平高科等上市公司年度审计报告; 2018年复核了益丰药房、天和防务、步步高等上市公司年度审计报告。 |
2、诚信记录
项目合伙人、签字注册会计师、项目质量控制复核人近三年不存在因执业行为受到刑事处罚,受到证监会及其派出机构、行业主管部门等的行政处罚、监督管理措施,受到证券交易所、行业协会等自律组织的自律监管措施、纪律处分的情况。
3、独立性
天健会计师事务所(特殊普通合伙)及项目合伙人、签字注册会计师、项目质量控制复核人不存在可能影响独立性的情形。
4、审计收费
2021年度天健拟收取财务报告审计及内部控制审计费用合计不超过人民币150万元。该笔费用参照有关规定,以业务量为衡量标准,请股东大会授权董事会与该所谈判为准。审计期间的食、宿等费用由公司承担。
二、拟续聘会计事务所履行的程序
(一)董事会审计委员会履职情况及审查意见
公司第十一届董事会审计委员会审议通过了关于聘请公司2021年度审计机构的议案,认为该所在接受聘请并在公司2020会计年度结束后,按照本公司年度报告的编制、披露的时间要求,认真组织、开展本公司2020年度的审计工作,并按与本委员会商定的审计工作时间安排提供书面的《2020年度审计计划》;在审计工作中严格遵循国家法律、法规,保持了独立性,做到了审计监督的客观性、公正性、权威性和有效性。
董事会审计委员会发表书面审查意见如下:
天健会计师事务所有限公司具有证券、期货从业资格,公司上市以来一直聘请该所为财务报告的审计机构。该所对公司的情况熟悉了解并工作严谨,决定向董事会推荐续聘该所为公司2021年度财务报告及内部控制审计的审计机构。
(二)上市公司独立董事关于本次聘任会计事务所的事前认可及独立意见
公司独立董事已就本次续聘会计师事务所事项发表了同意的事前认可意见,并发表了独立意见如下:
天健会计师事务所有限公司在接受聘请并在公司2020会计年度结束后,按照本公司年度报告的编制、披露的时间要求,认真组织、开展本公司2020年度的审计工作,并按与本委员会商定的审计工作时间安排提供书面的《2020年度审计计划》;在审计工作中严格遵循国家法律、法规,保持了独立性,做到了审计监督的客观性、公正性、权威性和有效性。
该所具有证券、期货从业资格,公司上市以来一直聘请该所为财务报告的审计机构。该所对公司的情况熟悉了解并工作严谨。我们同意续聘该所为公司2020年度财务报告及内部控制审计的审计机构。
(三)董事会会议的召开、审议和表决情况
2021年4月24日,公司召开了第十一届董事会第2次会议,公司现有九名董事,全体董事亲自参加了会议,符合《公司法》和《公司章程》的有关规定,所做决议合法有效。会议由蒋晓萌董事长主持,经审议与表决,以9票同意、0票反对、0票弃权,审议通过了关于聘请公司2021年度审计机构的议案。
(四)本次聘任会计师事务所事项尚需提交公司股东大会审议,并自公司股东大会审议通过之日起生效。
特此公告
- 报备文件
(一)公司第十一届董事会第2次会议决议;
(二)公司董事会审计委员会关于会计师事务所年度审计工作的总结报告暨续聘会计师事务所的决议
(三)独立董事的独立意见
(四)独立董事关于聘请公司2021年度审计机构的事前认可声明
浙江尖峰集团股份有限公司
董 事 会
二〇二一年四月二十七日
More information
The company fully deploys 2018 work
On January 27, the group company held a business analysis meeting to review and summarize the work in 2017, arrange and deploy the work for the new year, and put forward work requirements. At the meeting, various professional companies and directly affiliated enterprises reported on the overall work situation in 2017, focusing on analyzing the existing problems and deficiencies, and proposing corresponding solutions and work plans for 2018. Xiang Chongping, deputy general manager of the group company, systematically combed the current human resources efficiency and human resources development of the company. Chen Tianci, chairman of the board of supervisors, made a report and analysis on the "three reductions and three improvements" and the safety and environmental protection work in 2017. Lan Xiaolong, head of finance, analyzed the risks and challenges currently faced by the company according to the operating data and financial situation of its subordinate enterprises. The functional departments and offices of the headquarters also made a brief report on their annual work. Yu Jianhong, general manager of the group company, made a comprehensive review of the company's operation in 2017, compared and analyzed the main economic indicators of various industrial sectors, and pointed out that looking for new investment and development projects around strategic objectives, promoting the optimization of organizational structure and post setting, significantly improving the level of information management, improving the ability of fund management and tax planning, achieving certain results in scientific and technological innovation and technological transformation, and strengthening marketing management and market expansion, safety and environmental protection work is basically up to standard, training and talent development have achieved new results and other work highlights; at the same time, it summarizes and reflects on the shortcomings in strategic decision-making, management innovation, performance appraisal, market operation, and talent team building. After analyzing the current macroeconomic situation and the future trends of various related industries, Yu Jianhong informed
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-30
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
Jianfeng Pharmaceutical was rated as a provincial trademark brand demonstration enterprise
On December 28, 2017, Zhejiang Administration for Industry and Commerce announced the list of trademark brand demonstration counties (cities, districts), demonstration towns (streets) and demonstration enterprises in Zhejiang Province in 2017. Jianfeng Pharmaceutical Company was identified as a trademark brand demonstration enterprise, and it was also the only enterprise in Jinhua City to enter the list. Peak Pharmaceutical was established in 1998 and obtained the first registered trademark in 1999. Since then, Jianfeng Pharmaceutical has been actively carrying out brand building in accordance with the requirements of the Trademark Law and other laws and regulations, and has set up an intellectual property department to carry out trademark management, rights protection and other activities; it has established a sound trademark management system, strictly in accordance with the provisions of the Trademark Law to supervise and manage the use of trademarks inside and outside the enterprise, and safeguard the legitimate rights and interests of the enterprise. Establish strategic cooperation with professional institutions, for trademark applications, renewals and other work. In recent years, Jianfeng Pharmaceutical has also explored trademark investment, creating value through intangible assets such as trademarks and brands, promoting efficiency improvement, and further expanding corporate influence; at the same time, it has continuously increased investment in new product research and development and technological transformation, and actively Declare various patents to provide strong support for brand building with technological innovation. According to incomplete statistics, Jianfeng Pharmaceutical and its subsidiaries currently have more than 120 valid trademarks, including 1 well-known trademark in China, 2 well-known trademarks in Zhejiang Province, 5 well-known trademarks in Jinhua City, and 2 overseas registered trademarks; Obtained more than 40 domestic and international patents. Trademark is an important part of intellectual property rights, in the knowledge economy, brand effect is increasingly becoming the leading force of economic development.
2020
07-31
Peak Pharmaceutical Invests in Shanghai North Carolina to Build API R & D and Production Base
News from our newspaper On January 19, the group company held the second meeting of the tenth board of directors and reviewed and approved the "Proposal on Foreign Investment of Subsidiary Jianfeng Pharmaceutical." On the same day, Jianfeng Pharmaceutical signed an agreement to invest in Shanghai North Carolina Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Shanghai North Carolina") by acquiring shares and increasing capital. Shanghai Beika is a high-tech enterprise in Shanghai. It has an academician expert workstation and a number of Shanghai high-tech achievements transformation projects. It has won the title of "second prize for scientific and technological progress" in Songjiang District, Shanghai, "patent pilot enterprise" and "enterprise technology center" in Songjiang District, Shanghai. The company has strong research and development capabilities and has obtained 14 patents. At present, its main business is to provide products and customized services for domestic and foreign pharmaceutical companies. The products mainly include Tinib, alkaloids, carbohydrates and other anti-tumor drug intermediates. The customized services are mainly CDMO (contract development and manufacturing) of new drugs and intermediates. Shanghai North Carolina has two wholly-owned subsidiaries, Anhui Changtai Chemical Co., Ltd. (hereinafter referred to as "Changtai Chemical") and Anhui North Carolina Pharmaceutical Co., Ltd. (hereinafter referred to as "Anhui North Carolina"). Changtai Chemical is a pesticide manufacturer designated by the Ministry of Industry and Information Technology. It was established in July 2007. It now has three chemical synthesis workshops and a pesticide preparation compounding workshop, with 10 product approvals and 13 patents. Anhui North Carolina was established in December 2016. Its business scope includes the customization, production and sales of chemical raw materials and pharmaceutical intermediates, and the wholesale and retail of chemical raw materials and products (except hazardous chemicals
2020
07-31
The company was rated as an advanced unit of the city's focus on talent and love talent.
News from our newspaper On December 11, the Talent Work Leading Group of the Jinhua Municipal Committee of the Communist Party of China commended the advanced units of Jinhua City that value talents and love talents. 36 units including Jianfeng Group won this honor. The selection of advanced units that value talents and love talents is a measure taken by the Jinhua Municipal Party Committee to further create a good atmosphere of focusing on talents and loving talents, fully respect and make good use of the first resource of talents, serve innovation to drive development, and implement the development strategy of strengthening the province with talents and innovation. The enterprises and institutions that have won this honorary title have always regarded talents as the fundamental driving force for development for a long time, regarded the investment of talents as the most effective investment, and integrated the love of talents into the unit culture. Remarkable achievements have been made in gathering talents, achieving talents, transforming and upgrading, and accelerating development. The Jinhua Municipal Party Committee requires the majority of employers to learn from advanced units, vigorously promote the trend of focusing on talents and loving talents, remove the obstacles to the talent development system and mechanism, and in accordance with the requirements of "walking in the forefront and jointly building Jinhua", in order to promote the construction of a modern metropolitan area and accelerate the construction of the province An important growth pole for high-quality development provides talent support and intellectual guarantee. (this newspaper reporter)
2020
07-31